162220-83-9Relevant academic research and scientific papers
Synthesis and Purification of 6-Ethoxy-4-oxo-1,4-dihydro-[1,5] naphthyridine-3-carboxylic Acid Benzylamide
Beaudin, Justin,Meltz, Clifford N.,Meltz, Morgan,Phillips, James E.,Ragan, John A.,Brown Ripin, David H.,Singer, Robert A.,Tucker, John L.,Wei, Lulin,Bourassa, Dennis E.,Bowles, Paul,Castaldi, Michael J.,Clay, Ronald,Couturier, Michel A.,Karrick, Gregory,Makowski, Teresa W.,McDermott, Ruth E.
, p. 873 - 878 (2013/09/05)
The synthesis of 6-ethoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3- carboxylic acid benzylamide (1) on multikilogram scale is described. The major challenge for the synthesis of this quinolone GABA partial agonist was in the isolation of product of acceptable purity for clinical studies due to the insolubility of this compound. Also described are efforts to circumvent a high-temperature cyclization required for the synthesis of the quinolone ring system.
Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
-
, (2008/06/13)
The present invention encompasses structures of the Formula or the pharmaceutically acceptable non-toxic salts thereof wherein: x is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
Condensed 4-aminopyridines with antirheumatic activity
-
, (2008/06/13)
Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which one of A or B represents N and the other represents N or C--R3 ; R1 represents hydrogen, halo, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonylalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy, alkoxycarbonyl, alkanoylamino or carbamoylalkenyl; R2 represents hydrogen, alkyl, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R3 represents hydrogen or alkyl; R4 represents hydrogen, halo, alkoxycarbonyl, cyano, benzyloxycarbonyl, alkanoyl, benzoyl, alkyl, carboxy, alkylthio or carbamoyl; R5 represents hydrogen or alkyl; R9 represents hydrogen or alkyl; R10 represents phenyl, pyridyl or pyrimidinyl substituted by OR6 and optionally further substituted wherein R6 represents hydrogen, alkyl, alkoxycarbonyl or carbamoyl, alicyclic hydrocarbon, phenyl, cycloalkylalkyl, arylalkyl or pyridyl; or when R10 represents phenyl, OR6 represents a monosaccharide group or a disaccharide group; which are antirheumatic agents. Compositions containing these compounds and processes to prepare them are also disclosed.
